PhilosophyTeamPORtfolioInvestors
NewsBlogFAQsLet's Talk
PhilosophyTeamPortfolioInvestorsNewsBlogFAQsLet's Talk
Back To All Companies

AmacaThera

CareersTwitterLinkedInCompany Website
AmacaThera is based on the research of world-renowned biomaterials scientist Dr. Molly Shoichet. They are developing and commercializing a unique, injectable hydrogel platform technology for a wide range of medical applications, including post-operative pain management.
Founders

Mike Cooke
Dr. Molly Shoichet

Sector
BioTech
Location
Toronto, ON
Status
Active
Exited

AmacaThera News

PR Newswire
February 12, 2026
AmacaThera Named Life Sciences Ontario Emerging Company of the Year
BioXconomy
November 7, 2025
AmacaThera secures validation with $230M Pacira partnership
PR Newswire
November 4, 2025
AmacaThera Signs Exclusive Global Licensing Agreement with Pacira Biosciences for up to US$230 Million, Validating its Tunable Drug Delivery Platform
LinkedIn
November 21, 2024
AmacaThera Announces Phase 1 Results of First-in-Human Study
Newswire
January 4, 2023
AmacaThera Has Received Grant Funding From The Innovations for Vets QuickFire Challenge: Lung Cancer & Physical Trauma
Business Wire
February 22, 2021
AmacaThera Announces Close of Oversubscribed Series A Financing to Advance a Novel Post-Operative, Nonopioid Pain Therapy in Clinical Trials
CBC News
November 10, 2020
Engineering professor who designs gels to mimic human tissues wins Canada's top science prize
Newswire
October 20, 2020
AmacaThera to commence Phase 1 clinical trial for non-opioid, post-operative pain management
The Globe and Mail
StandUp Ventures portfolio founder Molly Shoichet is celebrated by The Globe and Mail for her injectable hydrogel platform technology